Pharmaceutical scientists have often been confronted with a problem regarding the formulation technologies of many injectable drugs with poor solubility or insolubility in water. Several approaches to obtaining parenteral formulations for water-insoluble or poorly soluble drugs have been reported and dispersion systems for drug delivery, such as emulsions, liposomes and nanospheres, are improving all the time. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] For instance, diazepam recently became commercially available in a lipid emulsion form, 13, 14) which was developed to reduce the incidence of local side effects after intravenous injection of conventional preparations of diazepam containing organic solvents. 7 ]nonyl)-3,7-dihydro-1H-purine-2,6-dione, see Fig. 1 ) is a newly synthesized adenosine A 1 -receptor antagonist. 15, 16) It was reported that KW-3902 has potent diuretic and renal protective activities in rats and dogs. [17] [18] [19] Additionally, KW-3902 induces a diuretic effect in various models of acute renal failure in rats 20, 21) and is expected to be of therapeutic benefit. In a previous study 22) we developed a lipid emulsion of KW-3902 as an injectable formulation, because KW-3902 is lipophilic (partition coefficient between n-octanol and water: log Pϭ 4.7) and water-insoluble (solubility is less than 1 mg/ml).
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For instance, diazepam recently became commercially available in a lipid emulsion form, 13, 14) which was developed to reduce the incidence of local side effects after intravenous injection of conventional preparations of diazepam containing organic solvents.
KW-3902 (1,3-dipropyl-8-(3-tricycle[3.3.1.0 3, 7 ]nonyl)-3,7-dihydro-1H-purine-2,6-dione, see Fig. 1 ) is a newly synthesized adenosine A 1 -receptor antagonist. 15, 16) It was reported that KW-3902 has potent diuretic and renal protective activities in rats and dogs. [17] [18] [19] Additionally, KW-3902 induces a diuretic effect in various models of acute renal failure in rats 20, 21) and is expected to be of therapeutic benefit. In a previous study 22) we developed a lipid emulsion of KW-3902 as an injectable formulation, because KW-3902 is lipophilic (partition coefficient between n-octanol and water: log Pϭ 4.7) and water-insoluble (solubility is less than 1 mg/ml).
However, it has been reported that intravenously injected emulsions and liposomes are rapidly captured by the reticuloendothelial system (RES) in organs such as the liver and spleen. [23] [24] [25] [26] [27] This is a major barrier to the delivery of drugs to non-RES tissues, and raises the specter that lipid emulsion formulations may affect the intrinsic therapeutic profiles of agents such as KW-3902 that target the kidney. 28) In the previous study 29) we examined the influence of an emulsion formulation on the pharmacokinetic profiles of KW-3902 and showed that this antagonist in lipid emulsions had pharmacokinetic parameters, which are similar to that it has in solution. This means that lipid emulsion formulation does not influence the intrinsic pharmacokinetics of KW-3902 after injection. From these results, it was thought that KW-3902 was extracted from the oil phase and partitioned rapidly into different components of the blood after injection. Moreover, it was confirmed that KW-3902 shows potent diuretic and renal protective activities even as a lipid emulsion. 21, 30) In this study, we investigated the dose dependent binding of KW-3902 from the formulation into blood components and defined the actual driving force behind the partitioning by in vitro experiment using lipid emulsions and liposome formulations. Moreover, the relative affinity of a drug to the formulations was defined as a parameter in order to evaluate the carrier potential, which is one of the properties of the formulations. In this report, the term "carrier potential" is defined as the ability of the formulations to retain the drug in its dispersed phase.
MATERIALS AND METHODS
Materials KW-3902 was synthesized at Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Japan). Egg yolk lecithin (containing 99% phosphatidylcholine), oleic acid and concentrated glycerin were purchased from NOF Corporation (Tokyo). Soybean oil was purchased from the Nisshin Oil Mills, Ltd. (Tokyo). All other chemicals were of reagent grade and obtained from Kanto Chemical Co. (Tokyo). Table 1 shows the formulation of the lipid emulsion of KW-3902 (em-KW-3902). The preparation was described earlier. 22) Briefly, KW-3902 was dissolved in soybean oil and mixed with egg yolk lecithin, oleic acid, concentrated glycerin and water for injection using a high-shear homogenizer (Model PVQS-1(3), Mizuho Industrial Co., Ltd., Osaka, Japan) at 8000 rpm for 15 min at 50°C. After adjustment of the pH to 7 with 1 N NaOH, the primary emulsions were passed through a microfluidizer (Model M-110EH, Microfluidics Corp., Newton, MA, U.S.A.) 5 times at 120 MPa. The emulsions were filtered through a 0.22 mm Ultipor filter (Pall Corp., East Hills, NY, U.S.A.), then packaged in 10 ml ampules (Type 1 glass) and sealed after nitrogen purging. The mean particle size of the em-KW-3902 was determined as 130 nm by dynamic light scattering (DLS-700, Otsuka Electronics, Osaka).
Preparation of Lipid Emulsion
Preparation of Liposome Table 1 shows the liposome formulation of KW-3902 (lipo-KW-3902). Lipo-KW-3902 was prepared by the method of Bangham et al. 31) KW-3902 and egg yolk lecithin were dissolved in isopropyl alcohol. The solvent was dried in vacuo, and the lipid films were hydrated with water containing glycerin by repeated vortex mixing. After that, the multilamellar vesicles were passed ten times through a polycarbonate membrane filter (Nuclepore, pore size 0.1 mm, Nomura Micro Science Co., Ltd., Tokyo) to size the liposomes by the method of Hope et al. 32) The mean particle size of lipo-KW-3902 was about 100 nm.
Preparation of KW-3902 Solution KW-3902 (50 mg) was dissolved in 5 ml of dimethyl sulfoxide. An aliquot of this solution (200 ml) was mixed with 200 ml of 1 N NaOH, and then diluted to 20 ml with saline (KW-3902: 0.1 mg/ml).
Electron Microscopy Negative-stain electron microscopy was performed to observe the morphology of the lipid emulsions according to the method of Magin and Weinstein. 33) Carbon-coated copper grids (150-B mesh) were purchased from Okenshoji Co., Ltd. (Tokyo). A drop of 2% ammonium molybdate was placed on the grid and removed after 8 min. The grid was air dried and then examined by electron microscopy (Hitachi H-7000, 75 kV voltage).
31 P-NMR Analysis 31 P-NMR spectroscopy was used to determine the distribution of phospholipids (PLs) between the outer and inner compartments of the particles in the lipid emulsions. 34) An aliquot of lipid emulsions (800 ml) was mixed with 15 ml of praseodymium chloride (PrCl 3 ) aqueous solution (0.2 mg/ml) and the out/in ratio was estimated from the ratio of intensities of shifted versus non-shifted 31 P-resonances. Spectra were recorded using a Bruker AMX400 spectrometer with a 31 P-probe, at 161.98 MHz. Acquisition time was 0.7 s. Cycling time was 2.7 s.
Blood Component Binding An aliquot of heparinized rat blood (5 ml) was incubated with KW-302 in each formulation at a concentration of 1, 10 and 80 mg/ml blood at 37°C for 30 min. Preliminary experiments revealed that the partition of KW-3902 between blood components and formulations came to equilibrium in 30 min. After incubation, the blood sample was centrifuged at 3000 rpm for 10 min at 10°C. Blood cell fractions were washed twice with saline and then KW-3902 was extracted with isopropyl alcohol. Plasma was fractionated by ultracentrifugation. 35) The density (d) of the plasma was adjusted to 1.006, 1.063 or 1.210 g/ml by adding a solution containing appropriate amounts of NaCl and NaBr. Each sample (200 ml) in duplicate was centrifuged at 40000 rpm for 3 h at 10°C (CP100a, HITACHI, Tokyo) using a PRL42T rotor (HITACHI). A 100-ml aliquot was collected from the uppermost layer of each tube, and then mixed with isopropyl alcohol. The concentration of KW-3902 in each fraction was determined by HPLC on a Shim-pack LCL-ODS column (5 mm, 150ϫ6 mm, Shimadzu Corporation, Kyoto, Japan). The mobile phase consisted of a mixture of acetonitrile and 0.02 mol/l potassium dihydrogenphosphate at 13 : 7 (v/v) delivered at a flow rate of 1.0 ml/min. A UV detector operated at 280 nm was used to detect and quantitate KW-3902. The sample floated at 1.006 g/ml was regarded as the fraction of chylomicron (CM) and very lowdensity lipoprotein (VLDL); that at 1.063 g/ml was regarded as CM, VLDL and low-density lipoprotein (LDL); and that at 1.210 g/ml was regarded as CM, VLDL, LDL and highdensity lipoprotein (HDL). The residues precipitated at 1.210 g/ml were defined as heavier proteins, which are lipoprotein deficient plasma fractions including glycoprotein and albumin. The amounts of KW-3902 in each fraction of heavier proteins, HDL, LDL and the combined fraction of CM and VLDL were calculated by successive subtraction.
Emulsion Fractionation Using the ultracentrifugation method described above but with saline instead of rat plasma, KW-3902 in the lipid emulsions or liposomes was fractionated. The sample that floated at 1.006 g/ml was regarded as a fraction of the lipid emulsions. A denser fraction corresponding to the density range of 1.006-1.063 g/ml was liposomes or liposome-like vesicles. Figure 2 shows electron micrographs of em-KW-3902 obtained using the negative-staining method. The diameter of the emulsion particles in em-KW-3902 was about 120 nm, which is consistent with the result of the light scattering analysis. In the electron micrographs (Fig. 2) , the liposome-like vesicles are also visible in the emulsions, where the partial lipid lamellae were found. The diameter of the vesicles was about 80 nm for both emulsions. Other small particles with a diameter of about 50 nm are visible in these photo images. Figure 3 shows the 31 P-NMR spectra of em-KW-3902. 31 P-NMR spectroscopy was used to detect the liposome-like vesicles, in which PLs distribute between the outer and inner compartments of the vesicles. Adding PrCl 3 resulted in a shift of the spectra downfield, which distinguishes between the two groups of PLs. The peak shifted to downfield was attributed to PL-headgroups accessible to PrCl 3 , i.e., 'out'-side A sufficient quantity to make 1 ml A sufficient quantity to make 1 ml of the vesicles. In contrast, the spectra remaining at about 2 ppm were PL-headgroups inaccessible to PrCl 3 , that is, 'in'-side of the vesicles. The out/in ratio of PLs was estimated from the intensities of 31 P-resonances following addition of PrCl 3 , and then that of em-KW-3902 was 3.2.
RESULTS

Physical Structure of Lipid Emulsion
Fractionation of KW-3902 in the Formulations Using the ultracentrifugation method, em-KW-3902 and lipo-KW-3902 were fractionated according to the density. The sample floated at 1.006 g/ml is regarded as a fraction of the lipid emulsions, because the density of soybean oil is about 0.916-0.922 g/ml. 36) A denser fraction detected in the density range of 1.006-1.063 g/ml corresponds to liposomes or liposome-like vesicles, according to the result of lipo-KW-3902 mentioned below. As we reported in the previous paper, 29) em-KW-3902 showed the KW-3902 distribution in which 78.8% was in the fraction of dϽ1.006 g/ml and 21.2% in 1.006-1.063 g/ml, corresponding to liposomes or liposome-like vesicles. In the case of lipo-KW-3902, 100% of KW-3902 was detected in the density range of 1.006-1.063 g/ml. No KW-3902 was detected in the fraction heavier than 1.063 g/ml; this means that most of the KW-3902 distributes in the oil droplets, i.e., emulsions and liposomes, instead of the water phase because of its lipophilic character.
Incubation with Rat Blood The association of KW-3902 with rat blood components was studied by ultracentrifugation. The distributions of KW-3902 between blood fractions obtained after spiking of rat blood with free-KW-3902, em-KW-3902 or lipo-KW-3902 are presented in Table 2 . The amounts of KW-3902 spiked in rat blood were 1, 10 and 80 mg/ml.
In the case of free-KW-3902, the amounts recovered from the fractions of blood cells, heavier proteins, HDL, LDL, and the combination of CM and VLDL were 12.7, 50.2, 31.9, 2.7 and 2.5%, respectively, at 1 mg/ml blood level (Table 2) . When free-KW-3902 was spiked at 10 mg/ml blood, the distribution mode of KW-3902 to the blood fractions was similar to that at 1 mg/ml blood level. In contrast, the amount of KW-3902 recovered from the fraction of blood cells increased to 22.8% when incubated at 80 mg/ml blood.
After incubation with em-KW-3902, the distribution of KW-3902 in the blood components was similar to that with free-KW-3902 at the dose of 1 mg/ml blood. The higher the amount of KW-3902 spiked, the more is KW-3902 in the density of dϽ1.063 g/ml, which corresponds to the density of lipid emulsions; about 65% of the dose was detected in this range when em-KW-3902 was incubated at 80 mg/ml blood. This confirms that the KW-3902 remaining in the lipid emulsion particles was assimilated into the lipoproteins, i.e., CM, VLDL and LDL.
The same tendency as em-KW-3902 was observed for lipo-KW-3902, though the density range was 1.006-1.063 g/ml instead of dϽ1.063 g/ml, because the density of liposomes corresponds to this fraction.
Assuming that the amount transferred to another density fraction after incubation with rat blood is the consequence of the release from the original formulations, we calculate the in vitro % release of KW-3902 from the formulations as follows: first, subtracting the amount (%) of KW-3902 in the density fraction of dϽ1.063 g/ml of free-KW-3902 from that of em-KW-3902 in the same fraction range gives the amount (%) of KW-3902 remaining in the original fraction. Then, subtracting the calculated remaining amount (%) of KW-3902 from 100 gives the in vitro % release. In the case of lipo-KW-3902, calculate the in vitro % release using the fraction of 1.006-1.063 g/ml instead of dϽ1.063 g/ml. When the remaining amount of KW-3902 showed negative value, it was calculated to be 0%. Figure 4 shows the in vitro release profile of KW-3902 from each formulation. KW-3902 was released completely from the lipid emulsions and the liposomes after incubation at 1 mg/ml. In contrast, the remaining amount of KW-3902 in 996 Vol. 26, No. 7 'in' and 'out' correspond to PL-headgroups inaccessible or accessible, respectively, to the reagent. lipid emulsions and liposomes was about 50 and 60%, respectively, when incubated at 80 mg/ml.
DISCUSSION
In a previous paper, 22) we reported the development of a lipid emulsion of KW-3902 suitable for injection, since the compound itself is lipophilic and water-insoluble. Lipid emulsions have been employed as carriers for lipophilic drugs with some clinical success. 5, 6, 13, 14) However, RES readily takes up the oil droplets of conventional lipid emulsions, [23] [24] [25] the carrier potentials of which are reported to be low. 37) It has also been shown that the liposome-like vesicles coexist with typical o/w emulsions in commercial parenteral emulsions. 34, [38] [39] [40] Moreover, it has been reported that liposomes show different pharmacokinetics from emulsions, 23, 41) because of the difference in the affinity for a series of apolipoproteins [42] [43] [44] [45] [46] [47] or the subsequent metabolism by the lipoprotein lipase. 34, [48] [49] [50] Férézou et al. 34) investigated the influence of the ratio of PLs to triacylglycerols (TGs) in parenteral emulsions on the distribution of their fat particles and correlated the amount of liposome-like mesophase to PL/TG ratio. Em-KW-3902 has a large amount of egg lecithin, the mixing ratio of PL to oil being 1 : 1, to give a mean particle size of 130 nm. 22) The presence of liposome-like vesicles was confirmed by electron microscopy (Fig. 2) . These vesicles were about 80 nm in size, which is consistent with the findings of Férézou 34) and Rotenberg and their colleagues.
38)
Using 31 P-NMR analyses, we estimated the amount of the liposome-like vesicles in the lipid emulsions quantitatively from the out/in ratio of PLs in em-KW-3902. Taking into account the fact that the typical liposomes with the mean size of 80-100 nm has the out/in ratio of about 1.1, 38) 50% of the total PLs formulated in em-KW-3902 corresponds to the liposome-like vesicles. We also assessed the amount of KW-3902 distributed in these vesicles utilizing the ultracentrifugation method, and found that about 20% of the KW-3902 formulated in em-KW-3902 was present in them.
Since it has become apparent that KW-3902 distributes in two types of particles, lipid emulsions and liposomes, it is worthwhile elucidating the influence of the liposome fraction on the performance of KW-3902 lipid emulsion formulation. It is useful to express the carrier potentials by their numerical value to compare the performance of the formulations. Therefore, we attempted to establish a method to evaluate the carrier potentials by in vitro experiment using these two formulations as model formulations (Table 1) . Takino et al. investigated the physicochemical interactions between drugs and formulations using four radiolabeled lipophilic compounds to develop long-circulating emulsion carrier systems. 51) In their study, lipophilic drugs with a low log P were rapidly released from oil droplets by dilution after injection, and highly lipophilic drugs with log P values larger than 9 were required to achieve a stable incorporation into the emulsion carrier.
In this study, our attention was focused on the phenomenon that the drug released from formulations into blood components, and on evaluating the relative affinity of the drug between two different phases. A new parameter was defined to assess the carrier potentials of the formulations instead of the partition coefficient of drugs in the oil/water system (log P), because we need a comprehensive understanding of the subject matter based on consideration of properties of the formulations.
Investigation of the dose-dependency of the physicochemical interactions of drugs between formulations and blood components will provide significant information on the development of dispersion formulations, especially for lipid emulsion formulation. The in vitro blood component binding experiment showed the dose dependent release of KW-3902 from the lipid emulsions or liposomes (Fig. 4) . In other words, the amount of KW-3902 retained in the formulations increased with increase in the ratio of formulation volume to the rat blood. Taking into account the solubility, KW-3902 was believed to be binding to the blood components such as plasma proteins and blood cells after its release from formulations, and the amount of KW-3902 dissolved in the plasma solution is small enough to be negligible. Suppose that a portion of V f ml of formulation, in which w mg of drug is contained, is mixed with the V b ml of rat blood; it will distribute between the two compartments, i.e., oil droplets or liposomes and blood components, and will reach an equilibrium, assuming that the amount of drug in the solution is small enough to be neglected. Let w b be the weight of the drug transferred into the blood components after incubation. The distribution of the drug between the two compartments can be described as:
(1) (2) or equivalently, (3) where K b/f is the relative affinity of the drug to the blood components. Equation 3 is inverted to obtain Eq. 4: (4) where w/w b is the inverse of the ratio of the amount transferred into blood components to the total amount of drug, and thus represented as 100/% released. The term of the inverse of the K b/f is related to K f/b . Then, Eq. 4 is represented as Eq. 5: (5) The relative affinity of the drug to the formulation (K f/b ) was obtained from the slope of 100/% released versus V f /V b plots. The good linearity confirmed the assumption that the mechanism of the drug release is the result of the proportional distribution (inset of Fig. 4) . The K f/b value for em-KW-3902 was 6.9 (rϭ1.000) and 8.0 (rϭ1.000) for lipo-KW-3902. This result reveals that KW-3902 shows higher relative affinity to the liposomes than the lipid emulsions. The fact that KW-3902 has a better affinity to the egg lecithin than the soybean oil supports this result. 22) Our objective was to formulate the KW-3902 in the lipid emulsions utilized as solvent, which would provide a vehicle for dissolving the drugs to prepare the injection, because the target tissue is not RES but kidney. 28) In this respect, the lipid emulsion formulation has an advantage.
We previously 29) investigated the influence of the emulsion formulation on the pharmacokinetics of KW-3902 using three different formulations: a lipid emulsion, a liposome and a saline solution, and found no significant difference in the pharmacokinetic parameters of the compound after injection of any of the formulations in rats. This confirmed that the lipid emulsions or the liposome formulations does not influence the intrinsic pharmacokinetics of KW-3902 and these formulations were defined as a solvent. In the present study, we were able to distinguish the carrier potential of liposomes from lipid emulsions for KW-3902 by utilizing the newly defined parameter K f/b ; however, most of the KW-3902 was released from formulations at the dose level of 1 mg/ml. Taking into account that the effective plasma concentration is less than 1 mg/ml, there would be no significant influence on the therapeutic profiles of KW-3902 between these two formulations. In the inset of Fig. 4 , the actual driving force behind the separating of KW-3902 from the lipid emulsions or liposomes was believed to be the proportional distribution into blood components. Moreover, it could be said that total amount of drug retained in the dispersion formulations depend on K f/b and the ratio of the volume of formulation to blood volume (inset of Fig. 4) . When dispersion formulations are developed, pharmaceutical scientists should consider the properties of the formulations comprehensively based on these two parameters: K f/b and the dosing formulation volume at the expected effective dose.
In summary, this study compared the carrier potential of the two formulations, a lipid emulsions and liposomes, by in vitro experiment. At a lower dose level, most of the KW-3902 was released from these two formulations, while more than half was retained in the formulations at a high dose level. This suggested that the carrier potential also depends on its dosing volume. The usefulness of the parameter, K f/b , was shown to be an indicator of carrier potential to assess the performance of the formulations.
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